bioMérieux launches GENE-UP® TYPER, an innovative diagnostic solution for food industries to rapidly analyze the root cause of contamination of *Listeria monocytogenes*

- **GENE-UP® TYPER is a real-time PCR* solution combining an assay and a web application for rapid strain characterization of microorganisms, and its first version GENE-UP® TYPER LMO targets *Listeria monocytogenes*.**
- **The solution helps to quickly identify the root cause of contamination and speed up the decision process to mitigate and further avoid future recurrence.**
- **This automated system offers a cutting-edge solution to the pathogen detection market with its speed, ease of use, and precision.**

Marcy-l'Étoile (France), February 13th, 2025 – bioMérieux, a world leader in the field of *in vitro* diagnostics, today announces the launch of GENE-UP® TYPER, a real-time PCR solution for rapid root cause analysis in the food industry.

Each year, an estimated 600 million people fall ill after consuming contaminated food, according to the World Health Organization (WHO)[1]. These incidents not only pose serious health risks but also lead to costly recalls and reputational damage for food industries. Despite strict monitoring and control measures, contamination can still occur. By using root cause analysis solutions, food industries can identify breakdowns in processes and implement effective corrective actions to better prevent future contaminations.

GENE-UP® TYPER is a real-time PCR solution for rapid strain characterization of microorganisms, for use on bioMérieux's GENE-UP® system. This easy-to-use automated food pathogen detection solution helps speed up the decision-making process by providing faster insights on strain identity.

After a pathogen is detected during routine testing and the strains are isolated in a sample, DNA is extracted and amplified with the GENE-UP® TYPER specific assay. The analytical result generated by the GENE-UP® instrument is then transferred to the AUGMENTED-DX web application. Powered by machine learning, which combines cutting-edge algorithms with years of expertise embedded in a comprehensive genomic database, GENE-UP® TYPER defines a unique address identifying the strain and groups identical strains into "clusters". The web application then progressively builds a history of the strain clusters present in the factory, allowing to trace back the source of contamination for an improved control of the production process.

"With more than 30 years of expertise in Industrial Applications, bioMérieux continues to heavily invest in disruptive science and technology to help the food processing industry keep pace with their rapidly changing environment. With GENE-UP® TYPER, we bring to the market an innovative solution capable of rapidly identifying root causes through genomics and data utilization, participating in the collective effort to make the world a healthier place and fight against food insecurity. With our partner Mérieux NutriSciences, we share the same intent of reshaping the landscape of food safety and set augmented

PRESS RELEASE

quality standards", explains Yasha Mitrotti, Executive Vice President, Industrial Applications, bioMérieux.

This breakthrough and patented solution has been developed over years of research, with valuable contributions from Mérieux NutriSciences, a long-term partner of bioMérieux, a subsidiary of Institut Mérieux as well, and a global leader in food safety, quality and sustainability. Mérieux NutriSciences will retain co-exclusive rights to perform testing in key geographies for the outsourced testing services channel, ensuring the solution is available to all food and beverage processors, whether they operate an internal laboratory or outsource pathogen testing.

GENE-UP® TYPER LMO, the first assay targeting *Listeria monocytogenes* root causes using the GENE-UP® system, is now available worldwide for food manufacturers.

[1] *https://www.who.int/activities/estimating-the-burden-of-foodborne-diseases*

** Polymerase Chain Reaction*

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2023, revenues reached €3.7 billion, with over 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products.
www.biomerieux.com.

bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP

CONTACTS

INVESTORS RELATIONS

Aymeric Fichet
Tel.: +33 (0)4 78 87 20 00
investor.relations@biomerieux.com

MEDIA RELATIONS

CORPORATE
Romain Duchez
Tel.: +33 (0)4 78 87 20 00
media@biomerieux.com

UNITED STATES
Samantha Flynn (Junipr Public Relations)
Tel. : +1 (717) 413-0370
samantha@juniprcommunications.com

FRANCE
Laurence Heilbronn (Image 7)
Tel.: +33 (0)1 53 70 74 48
lheilbronn@image7.fr

PRESS RELEASE